It's estimated that one in eight women will be diagnosed with breast cancer in their lifetime. 75% of women who are diagnosed have no known risk factors. But the incidence and mortality rate of breast cancer has declined over the last couple of decades. The government released controversial amendments to screening recommendations last year based on mortality outcomes from breast cancer. What are the implications for our patients, and what screening guidelines should advanced practice clinicians recommend to patients? Nurse practitioner Constance Roche, a clinical coordinator at the Avon Comprehensive Evaluation Center in Boston, Massachusetts, joins host Mimi Secor to discuss how to identify high risk patients, the best screening techniques and how primary care providers can find the best specialist for their patients.
What Advanced Practice Clinicians Need to Know About Diagnosing and Treating Breast Cancer

Transcript
What Advanced Practice Clinicians Need to Know About Diagnosing and Treating Breast Cancer
closeReady to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
It's estimated that one in eight women will be diagnosed with breast cancer in their lifetime. 75% of women who are diagnosed have no known risk factors. But the incidence and mortality rate of breast cancer has declined over the last couple of decades. The government released controversial amendments to screening recommendations last year based on mortality outcomes from breast cancer. What are the implications for our patients, and what screening guidelines should advanced practice clinicians recommend to patients? Nurse practitioner Constance Roche, a clinical coordinator at the Avon Comprehensive Evaluation Center in Boston, Massachusetts, joins host Mimi Secor to discuss how to identify high risk patients, the best screening techniques and how primary care providers can find the best specialist for their patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?
HF Management for Patients with Comorbid Conditions
Personalizing Care Within the RCC Treatment Paradigm
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?